The impact of admission procalcitonin on prognosis in acute coronary syndromes: A pilot study

Biomarkers

Volumn 17, Issue 1, 2012, Pages 56-61

  Picariello, Claudio ^a   Lazzeri, Chiara ^a   Attan, Paola ^a   Chiostri, Marco ^a   Gensini, Gian Franco ^a   Valente, Serafina ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Acute coronary syndromes; Cardiogenic shock; Mortality; Procalcitonin; Prognosis

Indexed keywords

PROCALCITONIN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PILOT STUDY; PROGNOSIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; CALCITONIN; DIAGNOSTIC TESTS, ROUTINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENSIVE CARE UNITS; ITALY; MALE; MIDDLE AGED; PATIENT ADMISSION; PILOT PROJECTS; PROGNOSIS; PROTEIN PRECURSORS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SHOCK, CARDIOGENIC; TROPONIN I;

EID: 84856467495     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.638398     Document Type: Article

References (26)

1. Ataoglu HE, Yilmaz F, Uzunhasan I, Cetin F, Temiz L, Döventas YE, Kaya A, Yenigün M. (2010). Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res 38:52-61.
2. Biasucci LM, Biasillo G, Stefanelli A. (2009). Procalcitonin and acute coronary syndromes: a new biomarker for an old disease. Intern Emerg Med 4:363-365.
3. Buratti T, Ricevuti G, Pechlaner C, Joannidis M, Wiedermann FJ, Gritti D, Herold M, Wiedermann CJ. (2001). Plasma levels of procalcitonin and interleukin-6 in acute myocardial infarction. Infammation 25:97-100. (Pubitemid 32295745)
4. Calif RM, Bengtson JR. (1994). Cardiogenic shock. N Engl J Med 330:1724-1730. (Pubitemid 124005035)
5. Geppert A, Steiner A, Delle-Karth G, Heinz G, Huber K. (2003). Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 29:1384-1389. (Pubitemid 37041172)
6. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Windecker S, Achenbach S, Badimon L, Bertrand M, Bøtker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Rof M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P; Authors/Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. (2011). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Te Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. (In Press).
7. Hochman JS. (2003). Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107:2998-3002. (Pubitemid 36758968)
8. Kafkas N, Venetsanou K, Patsilinakos S, Voudris V, Antonatos D, Kelesidis K, Baltopoulos G, Maniatis P, Cokkinos DV. (2008). Procalcitonin in acute myocardial infarction. Acute Card Care 10:30-36. (Pubitemid 351878178)
9. Kelly D, Khan SQ, Dhillon O, Quinn P, Struck J, Squire IB, Davies JE, Ng LL. (2010). Procalcitonin as a prognostic marker in patients with acute myocardial infarction. Biomarkers 15:325-331.
10. Lazzeri C, Bonizzoli M, Cianchi G, Gensini GF, Peris A. (2008). Troponin I in the intensive care unit setting: from the heart to the heart. Intern Emerg Med 3:9-16.
11. Lazzeri C, Sori A, Chiostri M, Gensini GF, Valente S. (2009). Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention. Eur J Anaesthesiol 26:856-862.
12. Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF. (2010a). Microalbuminuria in hypertensive nondiabetic patients with ST elevation myocardial infarction. J Cardiovasc Med (Hagerstown) 11:748-753.
13. Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF (2011a) Acute glucose dysmetabolism in the elderly with ST elevation myocardial infarction submitted to mechanical revascularization. Int J Cardiol Feb 21. [Epub ahead of print]
14. Lazzeri C, Valente S, Chiostri M, Sori A, Bernardo P, Gensini GF. (2010b). Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with infammatory markers: a single center experience. Int J Cardiol 138:206-209.
15. Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C, Gensini GF. (2010c). Prognostic values of admission transaminases in ST-elevation myocardial infarction submitted to primary angioplasty. Med Sci Monit 16:CR567-CR574.
16. Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C, Gensini GF. (2011b). Te prognostic role of gamma-glutamyltransferase activity in non-diabetic ST-elevation myocardial infarction. Intern Emerg Med 6:213-219.
17. Picariello C, Lazzeri C, Chiostri M, Gensini G, Valente S. (2009). Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Intern Emerg Med 4:403-408.
18. Picariello C, Lazzeri C, Valente S, Chiostri M, Attanà P, Gensini GF. (2010). Kinetics of procalcitonin in cardiogenic shock and in septic shock. Preliminary data. Acute Card Care 12:96-101.
19. Remskar M, Horvat M, Hojker S, Noc M. (2002). Procalcitonin in patients with acute myocardial infarction. Wien Klin Wochenschr 114:205-210. (Pubitemid 34298149)
20. Sentürk T. (2011). Measurement of procalcitonin in acute coronary syndrome. - Yet another prognostic biomarker. Circ J 75:1059-1060.
21. Sentürk T, Cordan J, Baran I, Ozdemir B, Güllülü S, Aydinlar A, Göral G. (2007). Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease. Acta Cardiol 62:135-141. (Pubitemid 46649230)
22. Sinning CR, Sinning JM, Schulz A, Schnabel RB, Lubos E, Wild PS, Papassotiriou J, Bergmann A, Blankenberg S, Munzel T, Bickel C; AtheroGene Study Investigators. (2011). Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 75:1184-1191.
23. Tygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefnition of Myocardial Infarction. (2007). Universal defnition of myocardial infarction. J Am Coll Cardiol 50:2173-2195.
24. Valente S, Lazzeri C, Chiostri M, Giglioli C, Sori A, Tigli S, Gensini GF. (2009). NT-proBNP on admission for early risk stratifcation in STEMI patients submitted to PCI. Relation with extension of STEMI and infammatory markers. Int J Cardiol 132:84-89.
25. Valente S, Lazzeri C, Chiostri M, Sori A, Giglioli C, Salvadori C, Gensini GF. (2008). Time of onset and outcome of cardiogenic shock in acute coronary syndromes. J Cardiovasc Med (Hagerstown) 9:1235-1240.
26. Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, Buller CE, Wong SC, Boland J, Dzavik V, Porway M, Pate G, Bergman G, Hochman JS; SHOCK Investigators. (2003). Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 42:1380-1386. (Pubitemid 37267276)